Here are the DEF 14A proxy statements from Aligos Therapeutics, Inc. (ALGS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ALGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALGS filings page.
Aligos Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Holders of 5,388,223 shares of voting common stock as of April 27, 2026 can participate. Proposals include re-electing two Class III directors, ratifying Ernst & Young LLP as auditor for 2026, and amending the 2020 Employee Stock Purchase Plan to remove its evergreen feature and lift the share reserve to 694,714 shares, an increase of 500,000. Stockholders will also cast advisory votes on 2025 executive compensation and on how often future Say-on-Pay votes should occur, with the Board recommending an annual frequency.